016
Directors Mr Glyn Denison Mr Jeffrey Edwards Dr Chris Quirk Company Secretary Mr John Palermo
Registered Office: 284 Oxford Street Leederville Western Australia 6007 Tel: +61 8 9443 3011 Fax: +61 8 9443 9960 www.obj.com.au ABN: 72 056 482 636
Licensing Term Sheets Executed – Delivery of First Devices
Licensing Term Sheets executed Shipment of first 200,000 devices
OBJ Limited (ASX: OBJ) is pleased to report the execution of two new Product Licensing Term Sheets with Procter & Gamble (P&G) as outlined in the recent Quarterly Report and an initial delivery of the first 200,000 devices to Procter & Gamble of products covered by these Licensing Term Sheets and Work Plans. This initial part-delivery of devices will be co-packaged with P&G skincare products prior to distribution through P&G’s global sales channels.
The first shipment under the newly-executed Licensing Term Sheets represents only the initial stocking volumes in a much larger roll-out plan which will span multiple P&G brands. Dr Suda Sudarsana, Global SK-II R&D Franchise Leader stated: “OBJ helps us take our skin care experience to a new level by combining our knowledge and expertise in biology and chemistry with OBJ's expertise in diamagnetic and Physics, all in pursuit of leveraging science-based innovation to delight our consumers.” The new Licensing Term Sheets, referred to by the P&G internal codes of Wave I and Wave II, covers two types of devices developed by OBJ for use across multiple P&G brands.
About OBJ
OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.
OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.
OBJ RELEASE 6 May 2016
Registered Office: 284 Oxford Street Leederville Western Australia 6007 Tel: +61 8 9443 3011 Fax: +61 8 9443 9960 www.obj.com.au ABN: 72 056 482 636
About OBJ’s Technologies
OBJ has developed a platform of physical enhancement technologies based on lowcost magnetic micro-arrays that influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.
Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.
OBJ develops low cost micro-array film technology that utilise diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.
About P&G
P&G is the world’s largest consumer goods company with a brand portfolio containing over 300 household names – from Gillette to Olay and Head & Shoulders. With 130,000 employees, P&G provides global market access across 180 countries and serves some 4.4 billion consumers daily. P&G’s annual turnover is in excess of $US76 billion/annum.
For more information: OBJ Limited: 284 Oxford Street Phone: +61 8 9443 3011 Mr Glyn Denison – Director Leederville Fax: +61 8 9443 9960 www
- Forums
- ASX - By Stock
- Announcement
016 Directors Mr Glyn Denison Mr Jeffrey Edwards Dr Chris Quirk...
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WFL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable